Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9Y285
UPID:
SYFA_HUMAN
Alternative names:
CML33; Phenylalanyl-tRNA synthetase alpha subunit
Alternative UPACC:
Q9Y285; B4E363; Q9NSD8; Q9Y4W8
Background:
The Phenylalanine--tRNA ligase alpha subunit, also known by its alternative names CML33 and Phenylalanyl-tRNA synthetase alpha subunit, plays a crucial role in protein synthesis. It is responsible for the ligation of phenylalanine to its corresponding tRNA, a fundamental process in the translation of genetic information into functional proteins.
Therapeutic significance:
Linked to Rajab interstitial lung disease with brain calcifications 2, a disorder characterized by lung disease, growth delay, and brain abnormalities, the Phenylalanine--tRNA ligase alpha subunit's study could lead to novel therapeutic approaches for this and potentially other related conditions.